Table 2 Characteristics of lesions and treatment exposures included in the meta-analysis
Study | Group | Lesion GLD (μm) (mean ± SD) | Interventions | Number of Treatments (mean ± SD) (range) | Follow up duration (mo) | Diagnosis of PCV |
|---|---|---|---|---|---|---|
Mitamura (2010) | PDT | 3718 ± 1665 | PDT (6 mg/m2) | 1PDT | 3 | Presence of reddish-orange lesions; recurrent serosanguinous RPE detachments; dilated network of inner choroidal vessels with terminal hyperfluorescent aneurysm-like dilatations (polyps) on ICGA. |
Anti-VEGF | 3651 ± 1833 | IVB 1.25 mg | 3IVB | 3 | ||
Rouvas (2011) | PDT | NA | PDT (6 mg/m2) | 1.82(1–3)PDT | 12 | Identification of polyps and interconnecting vessels on the ICGA; presence of subretinal hemorrhages and/or exudation in the macula based on clinical examination |
Anti-VEGF | NA | IVR 0.5 mg | 6.9 (3–11)IVR | 12 | ||
Oishi (2013) | PDT | 3051.1 ± 1177.7 | PDT (6 mg/m2) | 1.8PDT | 12 | PCV was diagnosed based on the presence of polypoidal lesion depicted with ICGA |
Anti-VEGF | 3347.4 ± 1288.3 | IVR 0.5 mg | 2.5 IVR | 12 | ||
Koh (2012) | PDT | <5400 | PDT (6 mg/m2) + sham | 1.7(1–4) PDT | 6 | Presence of early subretinal focal ICGA hyperfluorescence; at least one of the following clinical criteria: presence of pulsatile polyp; presence of hypofluorescent halo; orange subretinal nodules in fundus photograph |
Anti-VEGF | <5400 | IVR 0.5 mg + sham | 5.2 (3–6)IVR | 6 | ||
Inoue (2013) | PDT | 3640 ± 2120 | PDT (6 mg/m2) | 1.52 ± 0.66 PDT | 24 | presence of clinical, OCT, FA and confocal ICGA findings showing a branching vascular network and polypoidal structures |
Anti-VEGF | 4171 ± 2631 | IVR 0.5 mg | 7.1 ± 5.2 IVR | 24 | ||
Kang (2014) | PDT | 2810.87 ± 974.10 | PDT (6 mg/m2) | 2.56 ± 0.38 PDT | 24 | PCV with subfoveal leakage on FA; presence of branching vascular networks and polypoidal lesions on ICGA |
Anti-VEGF | 2790.05 ± 871.50 | IVR 0.5 mg or IVB 1.25 mg | 10.12 ± 1.46 IVR/IVB | 24 |